Trial · NCT01341652
Results by group176
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 176
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 2-year Metastasis-Free Survival Rate | GM-CSF Alone | 42.3 | percent probability | ||
| 2-year Metastasis-Free Survival Rate | pTVG-HP Vaccine With GM-CSF | 41.8 | percent probability | ||
| Prostate Specific Antigen (PSA) Doubling Time (DT) | GM-CSF Alone | 8.9 | Full Range 1.6 to 77.9 | months | |
| Prostate Specific Antigen (PSA) Doubling Time (DT) | pTVG-HP Vaccine With GM-CSF | 5.4 | Full Range 1.8 to 77.9 | months | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Chills / Grade 2 | 2 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Chills / Grade 2 | 1 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Chills / Grade 3 | 0 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Chills / Grade 3 | 0 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Chills / Grade 4 | 0 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Chills / Grade 4 | 0 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Chills / Did not experience this AE | 47 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Chills / Did not experience this AE | 47 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Fatigue / Grade 2 | 2 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Fatigue / Grade 2 | 1 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Fatigue / Grade 3 | 0 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Fatigue / Grade 3 | 0 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Fatigue / Grade 4 | 0 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Fatigue / Grade 4 | 0 | Participants | |
| Number and Severity of Observed Toxicities | GM-CSF Alone | Fatigue / Did not experience this AE | 47 | Participants | |
| Number and Severity of Observed Toxicities | pTVG-HP Vaccine With GM-CSF | Fatigue / Did not experience this AE | 47 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01341652/results